Our Funded Published Research

The Wunder Project is a movement created by one doctor and one patient. A movement to get every person involved to change the face of cancer. Contrary to popular belief, it can be cured. The only thing standing in the way between patients and a cure is money, bureaucracy, and politics. The Wunder Project is creative, forward-thinking, and aggressive. The Wunder Project will not back down until we have raised every last cent of the $250 MILLION DOLLARS NEEDED FOR THE CURE and we will ensure that the process will not be held up by inefficiency, middlemen, or red tape. Yes, finding the cure will be nothing short of miraculous. But this is a miracle that we can achieve and a miracle from which we can all benefit. YOU CAN BE PART OF THAT MIRACLE. EVERY PERSON, EVERY DOLLAR, EVERY DISCUSSION COUNTS. You were born to kick cancer’s ass – join Dr. Lenz and Gloria in their mission to cure colon cancer. CANCER, YOUR TIME IS UP.

WunderGlo is proud to share these peer-reviewed and Published Research Papers Funded by The Gloria Borges WunderGlo Foundation for The Wunder Project.

2015

Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer

Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach

2016

Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy

Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab

Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012

Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients

Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection

2017

Tandem Repeat Variation Near the HIC1 (Hypermethylated in Cancer 1) Promoter Predicts Outcome of Oxaliplatin-Based Chemotherapy in Patients With Metastatic Colorectal Cancer

Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials

A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/ Bevacizumab or FOLFIRI/Cetuximab

Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer

Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection

Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer

Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial

Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials

2018

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials